T1	intervention 32 43	anastrozole
T2	control 48 57	tamoxifen
T3	ethinicity 116 124	Japanese
T4	outcome 1563 1573	PgR status
T5	outcome 1661 1694	changed from positive to negative
T6	iv-bin-abs 1577 1579	16
T7	intervention-participants 1580 1582	17
T8	cv-bin-abs 1624 1625	1
T9	control-participants 1626 1628	11
T10	outcome 1396 1405	ER status
T11	outcome 1423 1480	changed from positive at baseline to negative at 3 months
T12	iv-bin-abs 1409 1410	5
T13	intervention-participants 1411 1413	40
T14	cv-bin-abs 1520 1522	20
T15	control-participants 1523 1525	37
T16	intervention-participants 1115 1117	48
T17	control-participants 1137 1139	49
T19	total-participants 550 552	97
T20	eligibility 314 437	postmenopausal women with large, operable or potentially operable, locally advanced hormone receptor-positive breast cancer
T21	outcome 1164 1195	histopathological response rate
T22	iv-bin-percent 1275 1279	35.4
T23	cv-bin-percent 1284 1289	12.2%
T24	outcome 1310 1365	histopathological and clinical objective response rates
